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Background: Whole genome microarray gene expression profiling is the ‘gold standard’ for the discovery of
prognostic and predictive genetic markers for human cancers. However, suitable research material is lacking as
most diagnostic samples are preserved as formalin-fixed, paraffin-embedded tissue (FFPET). We tested a new
workflow and data analysis method optimized for use with FFPET samples.
Methods: Sixteen breast tumor samples were split into matched pairs and preserved as FFPET or fresh-frozen (FF).
Total RNA was extracted and tested for yield and purity. RNA from FFPET samples was amplified using three
different commercially available kits in parallel, and hybridized to Affymetrix GeneChip® Human Genome U133 Plus
2.0 Arrays. The array probe set was optimized in silico to exclude misdesigned and misannotated probes.
Results: FFPET samples processed using the WT-Ovation™ FFPE System V2 (NuGEN) provided 80% specificity and
97% sensitivity compared with FF samples (assuming values of 100%). In addition, in silico probe set redesign
improved sequence detection sensitivity and, thus, may rescue potentially significant small-magnitude gene
expression changes that could otherwise be diluted by the overall probe set background.
Conclusion: In conclusion, our FFPET-optimized workflow enables the detection of more genes than previous,
nonoptimized approaches, opening new possibilities for the discovery, validation, and clinical application of mRNA
biomarkers in human diseases.
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Cancer is a broad label, covering a variety of tumor sub-
types that are associated with different prognoses and
different responses to the various treatment options
available. Traditionally, solid tumors are studied by his-
topathologic assessment. However, as cancer is a hetero-
geneous molecular disease, classification of tumor types
should ideally be accompanied by molecular biology
techniques.
Gene expression profiling is a technology for identify-
ing the genes that are active in a given sample of cells or
tissue. This technique enables profiling of genes which
are differentially expressed in tumors, thereby providing
diagnostic and prognostic information for molecular* Correspondence: marlene.thomas@roche.com
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reproduction in any medium, provided the orsubclassification of tumors [1-4]. Gene expression profil-
ing of tumor samples using microarray technology has
promised more accurate prognoses and has the potential
to improve therapeutic options for patients [5,6]. Results
from such studies have already been translated into clin-
ical practice. For instance, gene expression profiling has
identified a powerful predictor of the outcome of disease
in young patients with breast cancer; this outperformed
standard systems based on clinical and histologic criteria
[7]. However, more research is needed before gene
expression profiling can become routine in the clinic.
The application of retrospective microarray analyses to
long-term archived tissues – as well as to fresh biopsy
samples that reflect the present disease state – could pro-
vide assistance in a number of areas. It may help in the elu-
cidation of disease mechanisms, in detection of novel
therapeutic targets, and in identification of prognosticl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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trials can also be used for identifying predictive markers [8].
Quantitative determination of genome-wide expression
levels via microarray technology also provides a powerful
approach for comparative analysis of normal and neoplastic
tissues.
Whole genome microarray gene expression profiling is
the ‘gold standard’ for the discovery of prognostic and
predictive genetic markers for human cancers [9]. Most
gene expression profiling studies use fresh-frozen (FF)
tissue, which yields high-quality RNA [9]. However, the
use of FF samples is currently not directly applicable to
tumor types that are characterized using histologic ana-
lysis, as the worldwide standard in this setting is forma-
lin fixation followed by embedding the fixed tissue in
paraffin. Collection and storage of fresh material would,
therefore, require a change in standard clinical protocols
as well as substantial additional logistical efforts, greater
demands on resources, and increased compliance for all
those involved with the collection and processing of
clinical trial samples. Formalin fixation and paraffin
embedding is the clinical ‘gold standard’ for tissue pres-
ervation as it preserves tissue architecture [10] and
allows the long-term storage of tissue in archival banks.
Millions of such archived samples provide a resource
that can be correlated with long-term clinical outcomes
[11]. As most diagnostic biopsies and surgically excised
samples available in tissue banks are formalin-fixed,
paraffin-embedded tissue (FFPET) samples, there is a
lack of suitable research material available for gene
expression profiling. Using archived specimens increases
the probability of identifying clinically relevant bio-
markers, so subjecting archived FFPET samples to gene
expression profiling could assist in the elucidation of
disease mechanisms, detection of novel therapeutic tar-
gets, and identification of prognostic markers. Further-
more, FFPET samples offer the most efficient means of
determining tumor profile (by detecting correlation be-
tween gene expression profiles and covariates such as
immune cell infiltration, and necrotic or fibrotic cell
content). It is, therefore, important that all techniques
used for examining tissue samples are optimized for
FFPET samples.
It is well documented that formalin fixation and par-
affin embedding degrades RNA in tissue samples
[10,12,13]. RNA derived from FFPET samples is not
only partially hydrolyzed but also chemically modified:
formalin reacts with nucleotides, leading to the intro-
duction of methylol groups into the bases. These
groups tend to further react and form intra- and inter-
molecular methylene bridges in RNA, DNA, and
protein [13]. These alterations can interfere with en-
zyme activity during the process of reverse transcrip-
tion, which is a critical step in microarray sampleprocessing. However, several researchers have demon-
strated that it is possible to extract RNA from FFPET
samples [14], although the poor quality of RNA derived
from FFPET samples means that reliable quantification
of gene expression is subjected to serious limitations.
In addition, differences in the formalin fixation tech-
niques, such as ischemia time and the fixation protocol
used, such as drying times, as well as storage time and
conditions, can all lead to differences in results for
gene expression [10,12,13].
There are also differences between the commercially
available kits used for RNA extraction and processing,
and so the use of different kits may lead to differences in
the results obtained. The results of RNA profiling are
expected to be platform-specific. Proper annotation of
probes and tailored data analysis also help in controlling
bias and reducing the variability of the results.
Archived specimens have no corresponding FF sam-
ples to act as comparator. Therefore, it is important to
ascertain the validity of any results obtained from using
FFPET samples. Research comparing gene expression
profiling in FF and FFPET samples has already been
done using various extraction and amplification tech-
niques and a variety of tissues, and it has been con-
cluded that valid data can be obtained from FFPET
samples [15-22], although results have been variable.
Gene expression profiling protocols for use with FFPET
samples continue to be explored, but further research is
needed to optimize and standardize RNA extraction and
amplification techniques and data analysis methods, so
that robust conclusions can be drawn from the results.
The aim of this study is to determine whether FFPET
samples are suitable for significant profiling analysis
using a new, optimized workflow and data analysis
method. The Affymetrix GeneChip® Human Genome
U133 Plus 2.0 Array platform was used and the results
from three different commercially available RNA ampli-
fication kits were compared. The three RNA amplifica-
tion kits were assessed in parallel and the expression
signatures of matched FFPET material and native FF
tissue from the same tumor were compared. If it can be
shown that gene expression profiling is possible from
FFPET samples, and that the profiling can detect stable
genes that display good signals, then using this opti-
mized system could reveal many more genes than previ-
ously reported from FFPET samples; this would be an
important step in disease biomarker discovery.
Methods
Tissue samples
Sixteen breast tumor samples (>12 months old) were
purchased from Asterand, Inc. (see asterand.com) for
information concerning ethical conduct, eight were es-
trogen receptor-positive (ER+) and eight were estrogen
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by immunohistochemistry and all samples consisted of
more than 70% of tumor cells.
Tissue preparation
Each tumor sample was divided into mirror sections,
half being FF and half being formalin-fixed and paraffin-
embedded using standard protocols. Total RNA was
extracted from 10 consecutive sections cut in each direc-
tion from the mirrored area. FFPET sections measured
10 μm and FF sections measured 15 μm. The purified
RNA from each fixation type was pooled. The first and
the last section for both FF and FFPET samples were
hematoxylin and eosin stained to exclude any significant
variations in the investigated tumor area.
Total RNA extraction
RNA extractions were performed according to the
manufacturers’ instructions as follows:
For FF cryosections, the RNeasy® Mini Kit and DNA
digestion step (QIAGEN AG) were used. For FFPET
sections, the High Pure FFPET RNA Isolation Kit® from
Roche Diagnostics was used.
RNA quality evaluation
The yield and purity of RNA was determined using a
NanoDrop 1000 Spectrophotometer (Thermo Scientific).
RNA integrity was measured using a Bioanalyzer (Agilent
Technologies) with either the RNA Nano or Pico Kit,
depending on sample concentration. The RNA Integrity
Number (RIN) and average length of the RNA were used
for sample characterization.
mRNA integrity in FFPET samples was measured using a
semiquantitative reverse transcription-polymerase chain re-
action assay (rtPCR). This assay is based on quantitative
amplification of 5′- and 3′-end sequences of the house-
keeping gene β-actin. Calculating the ratio of 3′ to 5′
amplicons allows for assessment of mRNA integrity: intact
RNA transcripts exhibit a ratio of 1, while degraded RNA
increases the ratio. A Transcriptor First Strand cDNA Syn-
thesis Kit (Roche) was used to prepare cDNA from 100 ng
of total RNA, using an anchored oligo(dT)-primer followed
by a subsequent amplification step with the SYBR Green I
Master on a LightCycler® 480 instrument (Roche Applied
Science). Genomic DNA residues were determined via
rtPCR using a LightCycler® 480, with 100 ng purified RNA
as template material.
Amplification and labeling
RNA samples from FF tissue were amplified using the
3′ IVT Express Kit (Affymetrix). Fluorescence labeling
and fragmentation were carried out according to the
manufacturer’s protocol.FFPET-derived RNA was amplified with either the
GeneChip® Expression 3′-Amplification Two-Cycle Kit
(Affymetrix), the WT-Ovation™ FFPE System V2 (NuGEN),
or the TransPlex® Complete Whole Transcriptome Amplifi-
cation Kit (Sigma/Rubicon Genomics).
Biotin labeling of the cDNA generated using the
Affymetrix technique was performed using the 3’ IVT
Express Kit (Affymetrix), while cDNA generated with
the NuGEN technique was performed using the FL-
Ovation cDNA Biotin Module V2 (NuGEN). Biotin
labeling of cDNA generated with the Sigma/Rubicon
Genomics technique was performed using the ULS™
aRNA Labeling Kit with Biotin-ULS for Affymetrix
Genechips (Kreatech Diagnostics).
Hybridization and processing
Hybridization of labeled probes on the Affymetrix
GeneChip Human Genome U133 Plus 2.0 Array were
conducted using the GeneChip® Hybridization, Wash,
and Stain Kit (Affymetrix).
Target preparation, hybridization of samples to
microarrays, and washing of microarrays were conducted
according to the respective manufacturers’ manuals. For
this workflow a GeneChip Fluidics Station 450 and a
GeneChip Scanner 3000 7G were used.
Data analysis
All analyses were performed using C and R statistical
data analysis developed at Roche. Extensive quality con-
trol of the wet-lab performance, such as background
signal and signal gradients, masking of spots (outliers),
and estimation of optical noise, was followed by gene ex-
pression index estimation. This was performed for every
amplification method separately with a modified version
of the Robust Multichip Average (RMA) renormalized
matched log algorithm [23].
To minimize annotation errors, the original Affymetrix
probe set design of the array was not taken into account.
Instead, every probe on the array (604,258 probes in
total) was first mapped against the latest human genome
build and transcriptome databases: UniGene, RefSeq,
and EMBL [24,25]. The probes that passed this first
quality control step were considered for the revised
probe set design. In order to make the results of the
present analysis comparable across multiple similar stud-
ies published so far, an in silico array design was created
that was as close to the initial Affymetrix design as pos-
sible, but which excluded misdesigned or misannotated
probes. Consequently, the original probe set was divided
into three subsets: a perfectly matching and unique part
(unique: 43,098 probe sets in total); a subset consisting
of probes that appear to match transcripts of multiple
genes (nonunique: 3,981 probe sets); and the remaining
probe sets that failed to match against either DNA or
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An example of a poor-quality original probe set is shown
in Figure 1. The value of the proposed in silico revision
is supported by the results of a t test to determine the
likelihood of an association between ER gene expression
patterns and ER status: whereas no significant associ-
ation was detected using the original Affymetrix probe
set design (P = 0.35), a strong association was detected
using the optimized probe set (P = 0.008). On close
examination, the original ER probe set can be seen to
contain four nonmatching probes and three nonunique
probes.
Ingenuity pathways analysis
Genes controlling the ER signaling pathway were identi-
fied in FF and FFPET samples using Ingenuity Pathways
Analysis (Ingenuity Systems).
Results
RNA yield and integrity
All samples yielded sufficient RNA to proceed to micro-
array processing, and most RNA samples were sufficiently
concentrated to enable an accurate assessment of integrity
using the RIN tool (lower limit = 25 ng/μl). RIN values were
obtained for all but five samples (all FFPET-derived). As
expected, RIN values indicated more degradation of RNA
in FFPET samples (RIN range, 1.8–2.8) than in FF samples




































Figure 1 Plot showing (A) typical poor-quality Affymetrix probe set a
corresponds to probe-dependent signal component, also known as affinity
red dots = ER+. * The set of 11 probes shown in Figure 1A contains seven
(probes 1 to 4) or that are not sufficiently specific for their target sequence
Concentrating on an unambiguous part of the probe set (Figure 1B) signifi
of 3.07 comparing expression in estrogen receptor-negative versus express
0.98 when the original Affymetrix probe set is used).3′/5′ ratios: ratios ranged from 4.2 to 151.3 in FFPET sam-
ples and from 1.0 to 1.5 in FF samples [Table 1].
The microarray plots also demonstrate that total
RNA from the FFPET samples showed more evidence
of degradation compared with total RNA from the FF
samples [Figure 2]. Of the three amplification kits
compared, the NuGEN amplification kit demonstrated
the closest correlation to the ‘gold standard’ FF results,
while the Sigma/Rubicon Genomics amplification kit
produced most deviated data [Table 2].
Percentage present calls
An alternative and more direct way of estimating the
percentage of genes expressed in a sample is by counting
the number of probe sets whose expression values ex-
ceed the limit of blank (LOB). LOB marks the lowest
level of expression that can definitely be attributed to
sample-derived human mRNAs. We estimated the LOB
value to be the 95% percentile of the expression of the
‘complete mismatch’ probe sets. The ‘complete mis-
match’ probe sets were composed of the probes that
failed to match both genomic sequence and known
mRNA and EST transcripts, even when up to three mis-
matches were tolerated. Table 2 shows that quantifica-
tion of probe sets achieved using the NuGEN RNA
amplification kit is similar to that achieved with ‘gold
standard’ FF amplification. For genes represented by at















nd (B) the revised probe set used in this study.* OY axis
profile. Signals are normalized by RMA method. Black dots = ER–,
probes that either do not match the genome and transcriptome
and may, therefore, detect multiple genes (probes 6 to 8).
cantly improves the power of the statistical tests used (eg, a t-statistic
ion in estrogen receptor-positive tumors as opposed to a t-statistic of
Table 1 RNA concentration, RNA integrity number and 3′/5′ ratios for fresh-frozen and formalin-fixed, paraffin-
embedded tissue samples
Sample FF samples FFPET samples
RNA conc. (ng/μL) RIN* 3′/5′ ratio RNA conc. (ng/μL) RIN 3′/5′ ratio
1 153 7.8 1.0 258 2.1 4.2
2 27 9.0 1.1 71 2.2 6.8
3 40 6.2 1.4 156 2.5 24.2
4 98 7.0 1.2 87 1.8 7.4
5 49 8.6 1.0 127 NA 5.1
6 73 7.3 1.0 96 NA 90.5
7 326 8.6 1.0 467 NA 90.8
8 87 6.8 1.2 168 6.2 44.3
9 34 5.4 1.5 74 NA 151.3
10 55 8.3 1.0 100 NA 90.8
11 23 6.9 1.2 53 2.6 9.0
12 120 7.9 1.0 162 2.8 72.2
13 58 7.7 1.1 71 2.6 17.1
14 110 6.9 1.1 178 2.5 11.3
15 121 7.8 1.1 219 2.3 16.6
16 175 7.1 1.2 349 2.3 16.1
FF, fresh-frozen; FFPET, formalin-fixed, paraffin-embedded tissue; NA, not assessable; RIN, RNA integrity number.
* RNA integrity is gauged using the RIN, which indicates the intactness of the sample by assigning a grade from 1 to 10, 10 being the most intact.
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probe sets. As an overall measure of the consistency we
estimated the percentage of genes for which the Pearson
correlation coefficient between related probe sets did not
exceed 0.5. Once again, gene expression data obtained
from FFPET samples processed using the NuGEN kit were
most closely comparable with FF samples.Sensitivity and specificity – whole genome
The FF sample results, as the ‘gold standard’, were as-
sumed to have 100% sensitivity and specificity for gene
detection. The sensitivity of a particular FFPET profiling
workflow was defined as the percentage of the probe sets
found ‘relevant’ by both the FF and the FFPET method
used. The threshold for relevance in the FF samples was
taken as a twofold increase or decrease in gene expres-
sion of ER+ and ER–. Once again, the best overall re-
sults were obtained using the NuGEN kit. Using the
NuGEN method, sensitivity, at 80%, was increased by 47
percentage points over the Affymetrix Two-Cycle kit,
and 65 percentage points over the Sigma/Rubicon
Genomics kit. Specificity, defined as the percentage of
the probe sets that showed relevant differential expres-
sion in FFPET samples but not in FF material, was
slightly lower using the NuGEN kit, at 97%, compared
with 99% for the Affymetrix Two-Cycle kit and 100% for
Sigma/Rubicon Genomics [Figure 3]. Similar resultswere obtained with a subset of genes from the ER signal-
ing pathway (data not shown).
Independent analysis of the expression of the gene DDX5
was undertaken as an internal control for validating the
results of the microarray data. DDX5 has been proposed to
be a very stable housekeeping gene, showing greater correl-
ation between quantitative rtPCR and microarray data than
GAPDH [26]. This analysis showed that processing FFPET
samples using the NuGEN amplification kit provided the
closest comparison with the FF sample processing. The
results obtained using the Affymetrix Two-Cycle kit
showed a wide scatter, unlike the FF sample, and results
obtained with the Sigma/Rubicon Genomics kit failed to
show expression of DDX5 (data not shown).
Signal detection sensitivity and specificity generally de-
pends on effect size. For this experiment, the sensitivity and
specificity were estimated independently for the couple of
subsets of genes that have effect size in a predefined range.
The results show that the larger the expected effect is in FF
samples, the easier it is to see the same effect in FFPET
samples. Dynamic sensitivity and specificity estimations
show the correlation of fold changes, such as a greater than
twofold increase between ER+ and ER–, in the FF samples
with the sensitivity of the corresponding FFPET sample.
Principal component analysis
Principal component analysis is a useful dimensionality















































































































Figure 2 Pre-normalization microarray plots. (A) Fresh-frozen tissue, (B) Formalin-fixed, paraffin-embedded tissue (FFPET) processed using the
Affymetrix Two-Cycle kit, (C) FFPET tissue processed using the NuGEN kit, and (D) FFPET tissue processed using the Sigma/Rubicon Genomics kit.
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ples are represented by several principal components ra-
ther than by the individual gene expression values
obtained from all probe sets. These components, some-
times called ‘super genes’, are linear combinations of
probe set expression values and are constructed in such
a way as to account for as much of the variability in the
data as possible.Comparison of the principal component analysis plots
[Figure 4] for matched FF and FFPET samples with ER+
and ER– status reinforces the similarity between data
obtained from FFPET samples processed using the
NuGEN amplification kit and the FF samples. FF and
FFPET samples displayed similar clustering of data
points, as well as similar sample order, overall shape,
and data distribution pattern.
Table 2 Quality measures of microarray gene expression values*
Correlation of gene expression











Median (25%, 75% quantiles) Median (25%,
75% quantiles)
FF: N/A 49.7 (47.3, 50.6) 51.4 17.4
FFPET:
Affymetrix
0.78 (0.72, 0.81) 33.4 (21.8, 38.1) 36.2 19.4
FFPET: NuGEN 0.88 (0.84, 0.89) 47.2 (44.1, 58.1) 52.7 17.9
FFPET: Sigma/
Rubicon
0.48 (0.47, 0.52) 22.9 (22.1, 24.6) 16.4 28.0
FF, fresh-frozen; FFPET, formalin-fixed, paraffin-embedded tissue; LOB, limit of blank; N/A, not applicable.
* For the genes represented by at least two probe sets the analysis of consistency of probe set expression is performed. As an overall measure of the consistency
we have estimated the percentage of genes for which the Pearson correlation coefficient between expression of all pairs of related probe sets did not exceed 0.5.
† As defined by the Affymetrix algorithm.
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The canonical ER pathway was extracted from the Inge-
nuity Knowledge Base and the fold changes in ER pathway
genes were mapped against those pathways [see Additional
file 1, Additional file 2, Additional file 3, Additional file 4].
The microarray expression data obtained for the ER
pathway matched known ER pathway biology, indicating
biologic plausibility for microarray data. While both
nonoptimized and optimized probe sets detected evidence
of a strong biologic effect associated with ER gene expres-
sion, a nonoptimized probe set would not have detected
many of the potentially significant but smaller-magnitude
changes in gene expression occurring within the tissue.
This effect is evident when sequence-detection sensitivity
values are compared across the ER-related probe sets
[Figure 3]. This result demonstrates that it is possible to
elucidate the same ER signaling network from both FF and
FFPET samples.Discussion
Gene expression profiling classifies individual tumors by
their gene expression patterns and may also describe
and predict therapeutic resistance and sensitivity pat-
terns. Profiling in several cancers, such as breast cancer,
colon cancer, lymphoma, leukemia, and melanoma [3],
has already identified molecular subclasses of tumors.
Identification of tumor subtypes may be predictive for
prognosis or response to drug therapy [6,7,28-31].
The potential of routine gene expression profiling to
predict clinical outcomes for cancer patients has yet to
be determined. The Evaluation of Genomic Applications
in Practice and Prevention Working Group stated in
2009 that there was “insufficient evidence to make a
recommendation for or against the use of tumor gene
expression profiles to improve outcomes in defined
populations of women with breast cancer” [32]. Clearly,more work needs to be done to translate promising re-
search findings into clinically relevant results.
Comparison of FFPET sample-derived gene expression
profiles with associated clinical outcome data could pro-
vide an invaluable resource for the investigation of
mechanisms of response and resistance to cancer thera-
peutics. This will, however, require a suitably reliable
method for extracting RNA from these samples and an
FFPET-optimized workflow for use in gene expression
profiling studies. Two recent studies performed using
archived FFPET core biopsies from the NOAH trial
(neoadjuvant trastuzumab with chemotherapy in patients
with locally advanced/inflammatory breast cancer) [33]
have demonstrated that biomarkers predictive of treatment
response can be identified from FFPET processed with an
optimized workflow such as that described here [34,35].
These findings speak to a vast untapped potential for
biomarker discovery due to the abundance of archived
tissues available for gene expression profiling.
FFPET samples could also be used prospectively to
identify biomarkers in clinical trials. Biomarkers discov-
ered via microarray gene expression profiling could then
be applied clinically using more widely available tech-
nologies, such as immunohistochemistry or quantitative
rtPCR. Recently, researchers conducting a multicenter
randomized phase III trial in colon cancer have sug-
gested that translational studies based on FFPET samples
should be included in prospective clinical trials [8].
Methods and protocols for RNA isolation from formalin-
fixed tissues have been available for over 20 years [13] but
results have been variable. Research continues to develop
optimized protocols for formalin fixation [36] and RNA
extraction methods [37].
The work reported here shows that there is no loss of
data if RNA amplification and in silico probe design pro-
tocols are optimized towards FFPET samples (which
were >12 months old). Specificity of gene detection was
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NuGEN method, and 100% using the Sigma/Rubicon
Genomics method. The gene detection sensitivity results
obtained from FFPET samples varied depending on
which of the three different amplification kits was used.
The combination of the NuGEN RNA purification/amp-
lification method with the Affymetrix Human Genome
U133 Plus 2.0 Array resulted in 80% sensitivity with 97%
specificity. This agrees with Linton et al. [21] who also
reported 80% sensitivity, assuming FF sensitivity to be
100%, using the same NuGEN amplification and labeling
system when comparing sarcoma FFPET with FF sam-
ples. Williams et al. [22] have also demonstrated the
superiority of the NuGEN method over the Affymetrix


































Affymetrix 488.0 229.0 32796.0 1
NuGEN 1187.0 961.0 32064.0
Sigma/Rubicon 
Genomics
218.0 82.0 32943.0 1
FN, false negative; FP, false positive; TN, true 
Figure 3 Estrogen receptor status of FFPET samples: sequence detect
a particular color in the plot represents the effect size (difference between
FFPET samples using a particular workflow. Different quadrants of the plot
false negative (FN) findings are those which are present in FF but absent in
effect size with the widely accepted threshold of 2-fold change (up or dow
not observed in our experiments, is when a relevant (>1 in absolute value)amplification systems (such as Affymetrix Sensation
Plus®) may increase the sensitivity and specificity of sig-
nal detection from FFPET. Furthermore, detailed feasi-
bility studies with FFPET samples that are >2 years old
should be carried out to provide further evidence that
archival tissue is suitable for gene expression profiling.
It is also important to show that the genes identified
in this new workflow are an accurate reflection of the
biology of the sample. The Ingenuity Pathways Analysis
shows that the same ER signaling pathway is identified
regardless of whether the sample was FF or FFPET, and
that therefore the FFPET data obtained are a true reflec-
tion of the biology of the tissue sample.
The correlation between gene expression profiling re-
sults obtained from FF and FFPET samples is greatly2 4 6
F
FN WP
002.0 0.0 33% 99%
303.0 0.0 80% 97%
272.0 0.0 15% 100%
negative; TP, true positive; WP wrong positive
ion sensitivity and specificity by different methods. Each point of
mean expression in ER+ and ER– samples) found in FF samples and
are marked so as to assist in classifying the findings. For example,
FFPET. Presence and absence is decided based on the observed
n). One particular case, referred to as a wrong positive finding (WP),


















































































Figure 4 Principal components analysis plots. (A) Fresh-frozen tissue, (B) Formalin-fixed, paraffin-embedded tissue (FFPET) samples processed
using the NuGEN RNA amplification kit, (C) FFPET samples processed using the Affymetrix Two-Cycle RNA amplification kit, and (D) FFPET samples
processed using the Sigma/Rubicon Genomics RNA amplification kit. Note the extremely similar shape of fresh-frozen and FFPET data clusters
associated with the NuGEN workflow. The NuGEN kit also provides the most parsimonious description: in order to capture the effect of estrogen
receptor (ER) status on gene expression, both the Two-Cycle and the Sigma/Rubicon Genomics kit would require at least two leading principal
components. Circles and triangles represent ER– and ER+ samples correspondingly. Technical replicates are shown in red.
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ing methods reported here. A comprehensive gene
expression profile is necessary to both the discovery of
novel biomarkers and the development of new disease
subclassifications. Our optimized sample processing
workflow and data analysis method enables the detection
of genes that cannot be detected using a nonoptimized
approach. The gene detection rate reported here forFFPET-derived samples is similar to that obtained using
FF samples, demonstrating the importance of optimal
RNA amplification and raw data processing with refined
probe set alignments, which could facilitate the discov-
ery of biomarkers from FFPET samples. In addition,
other commercial microarrays are now available which
may overcome the current limitations associated with
the Affymetrix GeneChip.
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to evaluate the overall quality of gene expression data.
However, if the percentage present call is to be used as a
quality control measure, then it may be advisable to set
a precise threshold for discarding poor-quality samples
so that potentially useful data – such as single gene
profiles obtained from individual samples – are not un-
necessarily lost. Consequently, the homogenous distribu-
tion of percentage present calls in the sample population
may be a more useful quality control measure than per-
centage present call alone. Using this method, a sample
with a markedly low percentage present call could be
identified as an outlier even in a genome-wide analysis.
The different techniques and kits used in gene expres-
sion profiling render direct comparisons with previously
reported data problematic. Although the redesigned
probe set used here is as close to the original Affymetrix
design as possible, comparisons with previously reported
data sets using the Affymetrix array may also be
problematic for several reasons. For example, differences
in FFPET techniques between laboratories result in vari-
able degradation of sample RNA. In addition, the age of
the sample can impact results, although Tanney and
Kennedy have reported that it is possible to extract
good-quality transcriptional data from samples as old as
17 years using the Roche High Pure FFPE extraction kit
and NuGEN WT-Ovation FFPE RNA amplification sys-
tem [14]. The quality of gene expression data can also
vary according to the RNA extraction and amplification
methods used.
Handling and fixation protocols vary between centers
and evolve over time, so the genetic variation identified
between tumors could be an artifact of tissue processing
rather than a reflection of tumor biology. To overcome
this, it may be important to pool samples from several
centers to ensure that they represent the population
under consideration as a whole [14]. This would require
careful study design to avoid adding confounding
factors.
It is also important to ensure that the sample size
selected is sufficient for the study to be adequately
powered to detect differences in gene expression. Most
tumor studies are aimed at finding genes with at least
twofold higher or lower expression than found in normal
tissues. Power analysis for this study (data not shown)
demonstrated that a protocol with 10 samples per
category was 40% powered to detect a twofold change in
expression, but could reliably detect a threefold change.
Conclusion
In conclusion, optimizing processing methods for use
with FFPET samples, together with optimized array
design and data processing, should provide a clinically
useful data set from the large archive of FFPET samplesalready available, and from FFPET samples routinely col-
lected in clinical trials. In addition, in silico probe set
redesign may enable the detection of potentially signifi-
cant but smaller-magnitude changes in gene expression
that may be diluted by the standard probe set back-
ground. The methods presented here have the potential to
enable a vast expansion in the quantity of gene expression
data available for analysis alongside other data, such as im-
munohistochemistry results. These findings suggest that it
is crucial to apply the most optimal sample processing ap-
proach concerning RNA amplification and subsequent raw
data processing, using the refined probe set alignment. Fi-
nally, this workflow could be beneficial for identifying po-
tentially novel disease markers, which have been missed in
previous data sets due to sensitivity or specificity issues. It
is important to further invest in optimizing the gene
expression profiling work flow to make sure that RNA in-
formation is interpreted correctly for the discovery, valid-
ation, and clinical application of mRNA biomarkers in
human diseases.
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